Kategori: SeaPRwire

Cyprus, EU, Mar 16, 2026 - March 16, 2026 - (SeaPRwire) - FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor's approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client's internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner's IBAN account infrastructure. During the second week the team activated card issuing and configured the platform's connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective "The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. "Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website: https://www.finharbor.com/

Cyprus, EU, Mar 16, 2026 - March 16, 2026 - (SeaPRwire) - FinHarbor recently announced a major update to its modular fintech infrastructure platform, expanding its crypto-fiat functionality and introducing a deeper orchestration layer across all modules. The updated platform bundles IBAN accounts, card issuing, payments and crypto-fiat exchange into a single stack, reducing typical launch timelines from more than a year to roughly one month. The company positions the platform as a ready-to-deploy foundation for fintech startups, embedded finance teams and licensed institutions that want to bring a financial product to market without building the entire stack internally. The problem it addresses Launching a neobank from scratch is still a long and expensive process. Most teams need 15–20 engineers, more than a year of development, and roughly €1.5–2 million before the first customer can even open an account. FinHarbor's approach is to remove much of that upfront work. The platform comes with core components already integrated: pre-built connectors to banking partners for IBAN and account infrastructure, card processing, payment rails, and crypto wallets. In practice, this means companies can start with a working financial product instead of assembling and connecting multiple vendors themselves. What changed in the new release The main change in the latest version is the introduction of a unified orchestration layer. Earlier versions of the platform offered modular components that could be connected together. The updated release adds a shared data model, a single audit log and compliance logic that operates across all modules. Clients now integrate through one API and operate under a single contract, while still keeping the option to replace individual components if needed. On the crypto side the platform has added extended custody capabilities for clients with specific blockchain integration requirements, broadening the range of supported networks and asset types. The compliance and AML tooling has also been updated, making it easier to configure the system to match each client's internal policies and risk frameworks across different jurisdictions. A recent deployment in four weeks One EU-licensed fintech company recently used the updated platform to launch a full neobank in 28 days, including IBAN accounts, card issuance and crypto-fiat exchange. The first week focused on core infrastructure: setting up the environment, integrating identity verification through SumSub, and connecting to the banking partner's IBAN account infrastructure. During the second week the team activated card issuing and configured the platform's connections to SEPA, SWIFT, and international payment rails provided by the licensed banking partner. The third week introduced the crypto layer – custodial wallets, exchange logic and fiat ramps. The final week was dedicated to integration testing, white-label interface customisation and the production launch. According to the company, the only noticeable delays were related to compliance approvals with the partner bank – a regulatory step rather than a technical limitation. Industry perspective "The new release is based on a simple idea: orchestration matters more than integration,” – said Ilya Podoynitsyn, CEO of FinHarbor. "Connecting APIs from several vendors isn’t the difficult part. The real challenge is making those components behave like a single product – with unified compliance rules, a shared audit trail and enough flexibility to avoid vendor lock-in. That’s the engineering problem we focused on solving.” Compliance and target users The platform includes built-in AML transaction monitoring, sanctions screening and configurable verification tiers. Suspicious activity reports can be generated in formats accepted by regulators, and every system action is recorded in a unified audit log accessible through the admin panel or API. Companies can operate under their own EMI, PI or VASP licence, or work through a licensed banking partner. The platform is designed to support both models and is aligned with regulatory frameworks such as MiCA and DORA. FinHarbor says the platform is primarily aimed at three types of clients: fintech startups launching an MVP, companies adding embedded financial services to an existing product, and regulated institutions – including banks or government organisations – that need on-premise infrastructure. It is best suited for companies looking to launch and iterate quickly on a proven infrastructure, rather than building every component from scratch. About FinHarbor FinHarbor is a technical platform provider for launching compliant, modular financial products – from wallets and neobanks to crypto ramps and OTC desks. Built on years of real-world fintech experience, the platform covers onboarding, compliance, wallets, transactions, cards, and reporting, delivered with a microservice-based architecture (ISO/PCI DSS-certified), a robust API layer, and on-premise or cloud-ready deployment. FinHarbor supports fiat-only, crypto-native, and hybrid business models across markets in Europe, MENA, and beyond. Learn more: www.finharbor.com Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Website: https://www.finharbor.com/

The Singapore-headquartered platform helps brands improve content reach and conversion in the era of short-form video and interest-based e-commerce. SINGAPORE – March 16, 2026 – (SeaPRwire) – As short-form video continues to reshape how information spreads and how consumers engage with brands, efficient collaboration between brands and creators has become increasingly important. Hello IP was built to address this need. Hello IP is a content distribution platform focused on social and interest-based e-commerce. By enabling brands to upload ready-made video content and distribute it through local creators across social platforms, Hello IP helps reduce the complexity of traditional creator collaborations, improve campaign efficiency, and create more sustainable monetization opportunities for creators. Under traditional creator marketing models, brands often face lengthy workflows that include influencer sourcing, repeated negotiation, contract signing, sample shipping, content review, and payment settlement. These processes can be slow, costly, and difficult to manage, especially in cross-border campaigns where shipping risks, inconsistent content quality, and uncertain outcomes remain common challenges. Hello IP offers a more efficient alternative. After brands upload content to the platform, creators can select tasks that match their style, audience, and interests, then distribute that content through their own channels. This model helps brands gain more localized and authentic exposure while allowing creators to earn performance-based rewards. To support faster market expansion, Hello IP has developed its core distribution system, Viral Engine, which combines creator distribution, influencer collaboration, advertising support, and cross-market strategies. The platform is currently active in mature TikTok e-commerce markets across Southeast Asia, the United Kingdom, and the United States, with content able to reach targeted creator communities in as little as 24 hours. For creators, Hello IP provides access to daily brand campaigns across categories such as beauty, mobile apps, e-commerce, and gaming. By lowering collaboration barriers and simplifying campaign participation, the platform helps creators unlock more stable income opportunities and build long-term commercial value. Mao Jianfeng, Founder of Hello IP, said, “In today’s creator economy, brands need content distribution models that are more efficient, scalable, and closely connected to local markets. Hello IP aims to build a smoother connection between brands and creators so that both sides can grow together.” As digital marketing enters a new phase, Hello IP’s connector model is creating a more efficient and inclusive path forward for the content ecosystem. About Hello IP Hello IP is one of ET CUBE’s core business pillars in the creator economy, focused on content distribution for social and interest-based e-commerce. Headquartered in Singapore, the platform connects brand content with local creator networks to help brands achieve faster, more authentic distribution and stronger conversion opportunities across key international markets. Media Contact Brand Name: Hello IP Website: https://www.helloipmcn.com

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients. The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance. More information about Desidustat Tablets and Renal Anaemia As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders. There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia. Desidustat Tablets have been approved for marketing in India. CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020. The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6 2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015 3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025) 4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012 CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order. As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients. The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026). Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster. As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2]. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval. The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. China Insights Consultancy’s industrial report 2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739. 3. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 4. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 11, 2026 – (SeaPRwire) – HYVE Promo today announced the launch of its AI-enabled print-on-demand platform designed to modernize Asia-Pacific’s corporate gifting and branded merchandise industry. While e-commerce in Asia has produced multi-billion-dollar unicorns, the region’s corporate gifting supply chain remains largely manual — dependent on spreadsheets, fragmented factory coordination, and week-long quote cycles. HYVE enters the market as a technology-first infrastructure platform built to streamline customization, printing, and cross-border fulfillment at scale. HYVE positions itself as the corporate gifting equivalent of Asia’s major e-commerce platforms — purpose-built for businesses that need fast, reliable, and compliant branded merchandise delivered across multiple markets. “Asia built some of the world’s largest e-commerce engines,” said Tim Ngiam, General Manager of HYVE. “But the corporate merchandise industry hasn’t kept pace. We built HYVE to bring platform thinking, AI-driven workflows, and print-on-demand efficiency to a sector still operating like it’s 2005.” AI-Driven Merch Infrastructure HYVE combines: AI-assisted artwork processing and print optimization Real-time production routing across decoration technologies Automated order batching for small and mid-sized runs Cross-border logistics orchestration for APAC distribution The platform integrates directly with HYVE’s high-capacity production hub in Ningbo, China, capable of processing approximately 500 orders daily. Small-batch corporate orders can ship in as little as 72 hours, serving markets including Singapore, Japan, Korea, India, Southeast Asia, and Greater China. Rather than operating as a marketplace aggregator, HYVE controls the full print-to-ship workflow — reducing supplier handoffs and production errors. Targeting a Rapidly Digitizing Market The global promotional products market is projected to reach US$37 billion by 2033, while Asia-Pacific corporate gifting is expected to exceed US$400 billion within the same timeframe. More than 40% of buyers now expect to manage merchandise orders digitally — from proofing to tracking to fulfillment. HYVE aims to become what its founders call “Asia’s largest merch engine” — a centralized infrastructure layer for corporate gifting across the region. “Marketers and procurement teams want the same simplicity they get when ordering consumer products online,” said Ethan Ung, Co-Founder and Chief Commercial Officer. “They don’t want to manage factories, chase quotes, or coordinate customs. They want speed, visibility, and certainty. That’s what a platform should provide.” Built for Enterprise and Regional Scale HYVE focuses initially on APAC enterprise buyers and distributors, offering: On-demand production Regional multi-country fulfillment Compliance-ready manufacturing standards Rapid turnaround for campaign-driven activations The company plans to expand product categories, introduce deeper AI automation across artwork and routing, and integrate with marketing and e-commerce ecosystems used by enterprise teams. About HYVE Promo HYVE Promo is a Singapore-based technology platform modernizing corporate gifting across Asia-Pacific. Backed by the founders of BrandCharger and Headwind Group, HYVE operates a vertically integrated print and fulfillment engine designed to bring AI-driven efficiency, transparency, and scalability to branded merchandise distribution. For more information, visit: https://hyve.promo Media Contact Ming Yi Lim, Marketing Manager HYVE Promo Pte Ltd mingyi.lim@hyve.promo

SINGAPORE – March 09, 2026 – (SeaPRwire) – AI Labs, an AI-driven crypto trading technology company backed by Academic Labs, announced the launch of an AI-assisted platform designed to help cryptocurrency traders analyze market data and respond more efficiently to changing market conditions. As automated tools and algorithmic strategies become more common in global digital asset markets, the platform integrates visual analysis, narrative data monitoring, and automated trade execution features intended to support more structured and data-driven trading decisions. The fastest traders in today’s crypto markets may not always be humans. As digital asset markets increasingly incorporate automation, many traders now rely on algorithmic systems that can monitor markets continuously and react to signals with minimal delay. A crypto project called AI Labs (ticker: AIX) is building an AI-enabled platform that combines visual reasoning, narrative intelligence, and automated execution to help users interpret market data and respond to signals more efficiently than traditional manual analysis alone. “Markets are entering an era where the use of artificial intelligence is becoming more common in trading strategies,” said Kingston Kwek, owner of AI Labs. “Our goal is to make analytical tools that are often used by institutional trading teams more accessible to a wider group of crypto traders.” At the center of AI Labs’ platform is a visual reasoning engine that analyzes charts not simply as static images, but as evolving market structures. Using computer vision and multimodal AI techniques, the system can identify potential liquidity zones, resistance levels, and broader market patterns within short timeframes. Alongside this, AI Labs has developed a narrative intelligence layer that scans information across the crypto ecosystem. This includes movements associated with large crypto wallets, developer updates, and shifts in online sentiment—signals that traders often monitor when assessing possible market trends. Instead of only placing individual buy or sell orders, traders can define broader trading parameters using the AI system. The platform can then execute trades automatically based on predefined conditions, such as capital inflows, volatility changes, or funding-rate shifts. The objective is to help reduce emotional decision-making and allow traders to stay aligned with their strategies while automated systems monitor market activity continuously. AI Labs’ platform is currently onboarding new users, with reported monthly trading activity exceeding $1 billion across the platform. Media Contact Brand: AI Labs (Backed by Academic Labs) Contact: Media team Email: ryan@academic-labs.org Website: https://academic-labs.org

SHENZHEN, CHINA, Mar 5, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles. CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options. The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564. 2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23 3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 05, 2026 – (SeaPRwire) – Core Concepts Physio, one of Singapore’s leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain. Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved. To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked. A Smarter, More Complete Way to Diagnose Heel Pain Physiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support. The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in: More accurate, holistic diagnoses Fully optimised treatment strategies Fewer flare-ups and recurrences Clearer, consistent guidance for patients Faster and more sustainable outcomes “Many patients struggle because plantar fasciitis isn’t caused by just one issue,” said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. “It’s a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms.” A Case Study Demonstrating Collaborative Success In a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts. A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient’s daily load decreased significantly — allowing physiotherapy progress to continue without setbacks. Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running. “This case reflects what we see frequently,” said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. “Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery.” Making Multidisciplinary Care Accessible Nationwide Through this collaboration, patients with plantar fasciitis now benefit from: Joint physiotherapy–podiatry assessments Aligned clinical decision-making Consistent communication across providers A thorough evaluation of both the cause and consequence of heel pain A fully optimised recovery pathway “Our multidisciplinary team brings together the best of both professions,” said Mr Chng Chye Tuan. “Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands.” About Core Concepts Physiotherapy Core Concepts Physio is one of Singapore’s largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580. About Podiatry Quest Podiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care. Contact Details Organization: Core Concepts Pte Ltd Contact: Clemence Lim Email: marketing@coreconcepts.com.sg Website: https://www.coreconceptsphysio.sg

Base58 Labs Advances Integration of Proprietary BHLE Infrastructure LONDON, United Kingdom – March 04, 2026 – (SeaPRwire) – BASIS has announced a significant acceleration in platform development following its recent $35 million Pre-Series A capital raise. The funding enables parent company Base58 Labs to advance the commercial integration of its proprietary Base58 Hyper-Latency Engine (BHLE) into the BASIS staking infrastructure. BHLE, developed over multiple years within institutional high-frequency trading (HFT) research environments, is now transitioning from research phase into structured platform deployment. The engine is designed to enhance execution efficiency, reduce latency-related inefficiencies, and optimise liquidity management across fragmented digital asset markets. Industry observers note that the integration of institutional-grade execution frameworks into a staking infrastructure model represents a strategic evolution within the broader digital asset ecosystem. While detailed technical specifications remain confidential, Base58 Labs confirmed that BHLE will serve as a core execution layer within the BASIS architecture. In parallel with the technical acceleration, Base58 Labs has initiated a large-scale recruitment programme across Europe and the United Kingdom. The company is onboarding quantitative engineers, blockchain systems architects, and regulatory compliance specialists, all of whom will focus exclusively on BASIS platform development and infrastructure scaling. “Our objective is to combine years of proprietary research with expanded operational capacity,” a company spokesperson stated. “The recent capital raise enables us to consolidate technical, intellectual, and human resources around a single mission: delivering a high-performance staking infrastructure aligned with institutional standards.” BASIS is also being developed with regulatory alignment in mind, including adherence to emerging European frameworks such as MiCA (Markets in Crypto-Assets). The platform aims to provide a structurally robust environment for both institutional and retail participants. With liquidity reserves strengthened and integration milestones progressing, BASIS remains on track for an official launch in the second half of 2026. About Base58 Labs Base58 Labs is a London-based digital infrastructure company specialising in high-performance execution technologies and blockchain optimisation systems. Learn more: https://base58labs.com/ Media Contact Base58 Labs PR Team Email: info@base58labs.com BASIS Official Website: https://basis.pro/ Base58 Labs Official Website: https://base58labs.com/

Tashkent, Uzbekistan – March 04, 2026 – (SeaPRwire) – FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium – a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework. Why Uzbekistan – Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter. Asterium’s project is designed to operate fully within this framework. What Was Deployed – FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium’s business model. The core deployment covers three key layers: Banking infrastructure – management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems. Digital asset infrastructure – crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan’s Mirasmanda ledger for HUMO asset support. Compliance and exchange – a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off. The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards – all within a regulated environment. How the Partnership Works – FinHarbor operates as Asterium’s strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion. “This project required deep architectural customization – from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards,” said Ilya Podoynitsyn, CEO of FinHarbor. “The core phase is complete, and we are already scaling the platform with new products and business use cases.” What’s Next – With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform’s functionality to support additional business lines built on the deployed stack. About FinHarbor FinHarbor provides modular technology infrastructure for launching compliant financial products – from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets. Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Email: press@finharbor.com Website: https://www.finharbor.com/

Hong Kong – March 02, 2026 – (SeaPRwire) – At the India AI Impact Summit 2026, AI Safety Asia (AISA) convened two important conversations on the future of AI governance. The first examined how governments should respond when AI-related crises unfold across borders at machine speed. The second marking the launch of the International AI Safety Report 2026. Taken together, these sessions showed a change in the debate; moving past whether AI should be governed to a focus on how. Who verifies claims made by powerful systems? Who coordinates when an incident crosses jurisdictions in seconds? Who is responsible when an autonomous system acts, and no single ministry appears in charge? As AI systems become more agentic and embedded deeper into critical infrastructure, they are forcing diplomatic and regulatory institutions to respond in real time. The pressure on diplomatic and regulatory institutions is no longer just a theory, it is operational. Governing AI in a Fragmented World On 17 February at Bharat Mandapam, AISA co-hosted the session “AI Crisis Diplomacy: Governing AI in a Fragmented World” in partnership with the Center for Human-Compatible AI (CHAI) and the International Association for Safe and Ethical Artificial Intelligence (IASEAI). The session brought together senior experts in the space; Professor Stuart Russell, Audrey Tang, Dr. Yuko Harayama, Wan Sie Lee, and Azizjon Azimi, moderated by AISA’s Chief Strategy Officer, Adjunct Professor Alejandro Reyes. Rather than rehearse abstract debates about regulation, the discussion focused on plausible crisis scenarios: a cross-border deepfake incident that destabilises diplomatic relations before verification catches up; an AI-enabled cyberattack cascading across jurisdictions; an autonomous infrastructure system operating in one country, hosted in another, and affecting a third. The problem is not only detection. It is coordination under uncertainty. The familiar argument that AI evolves too quickly to regulate was put under scrutiny. The pace of innovation does not make governance obsolete. Aviation, nuclear energy, and pharmaceuticals are governed by setting acceptable risk thresholds and requiring evidence that systems meet them. AI should be treated no differently. Governments need to insist on demonstrable safety and credible liability frameworks, rather than accepting disclaimers and opaque risk claims. Governments already know how to cooperate during crises. Pandemic response and cybersecurity have shown that cross-border coordination is possible. The gap in AI governance is not diplomatic architecture in principle, but operational channels between those responsible for technical evaluation. Joint testing efforts are not only about measuring model performance. They build trust, and trust is what allows regulators to pick up the phone, compare signals, and verify before escalation spirals. AI does not create entirely new categories of crisis, but amplifies existing ones. What changes is speed and scale. Human institutions deliberate; AI systems act, and bridging that gap requires new protocols, shared verification standards, and regular engagement long before a crisis forces coordination under pressure. Governance capacity matters, and durable infrastructure outperforms isolated interventions. Crisis diplomacy cannot be improvised, it must be built through trusted networks, regionally grounded expertise, and repeat engagement. The Evidence Dilemma and the 2026 International AI Safety Report On 18 February, AISA co-hosted the International AI Safety Report 2026 Launch Reception at the High Commission of Canada in India, in partnership with the High Commission, the UK AI Security Institute, and Mila – Quebec Artificial Intelligence Institute. The event featured Professor Yoshua Bengio, Chair of the Report and Founder and Scientific Advisor of Mila, supported by co-leads Carina Prunkl and Stephen Clare. The report provides an independent scientific assessment of frontier general-purpose AI capabilities and risks; focusing on emerging risks, including malicious use, autonomous malfunctions, and systemic disruption, and confronts the evidence dilemma. Policymakers must act under conditions of uncertainty, yet waiting for perfect data runs the risk of leaving societies exposed. The Report documents rapid advances in reasoning systems and AI agents, as well as continued reliability challenges, risks in cyber and bio domains, and growing systemic concern; underscoring that risk management cannot rely on a single safeguard. Technical measures, institutional oversight, and societal resilience must be layered. The choice is not between innovation and safety, it is between unmanaged acceleration and accountable progress. Evidence standards, robust evaluations, and credible thresholds are essential if public trust is to keep pace with technical capability. For countries across Asia and the broader Global South, the issue is how to shape governance frameworks that reflect local institutional realities while contributing to global norms. AISA’s mission is to ensure that regional expertise informs both national decisions and international debates. From Conversation to Capacity AI governance is not a single regulatory instrument. It is an evolving institutional practice. The next phase will be defined less by declarations and more by whether governments can verify claims, share information at speed, and operationalise coordination before crises escalate. Asia is not waiting for governance models to arrive from elsewhere. Across the region, policymakers, regulators, and technical experts are building their own capacity to govern frontier technologies responsibly, shaped by local realities and regional priorities. The next AI-driven crisis will not unfold on a diplomatic timetable; it will move at machine speed. Whether diplomacy and safety can keep up will depend on the institutions, relationships, and verification channels being built now, not after the fact. About AI Safety Asia AI Safety Asia (AISA) believes progress in AI must begin with people. Since 2024, AISA has engaged more than 2,000 AI governance professionals across 16 Asian countries. Its work centres on building durable governance infrastructure: research that is regionally grounded, structured peer learning, and implementation-oriented engagement. AISA helps build capacity, bringing together policymakers, experts, and civil society to strengthen the knowledge, networks, and trust required to govern frontier technologies responsibly, grounded in regional realities. The institutions and relationships built today will determine whether diplomacy and safety can keep up. Social Link LinkedIn: https://www.linkedin.com/company/ai-safety-asia/ Media Contact Brand: AI Safety Asia Contact: Media team Email: contact@aisafety.asia Website: https://www.aisafety.asia

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

Kuala Lumpur, Malaysia - February 21, 2026 - (SeaPRwire) - DK88 Casino officially enters the Malaysia online casino market, introducing a fast, secure, and entertainment-driven online gaming platform designed specifically for players in Malaysia and Singapore. With a strong focus on immersive casino entertainment, DK88 is built for players who want more than just games — they want excitement, speed, and a platform they can trust. From seamless navigation to high-performance gameplay, DK88 Casino is engineered for today's digital generation. Players can explore the full experience directly through the official website at dashking88official.com, where registration, login, and access to promotions are designed to be fast and intuitive. A New Standard for Online Casino Entertainment in Malaysia The online casino market in Southeast Asia continues to grow rapidly, and Malaysia is at the center of this evolution. DK88 Casino enters the market with a clear mission: deliver a secure, transparent, and high-energy gaming experience tailored to local players. The platform offers a wide range of online slot titles, live dealer games, and interactive casino experiences. Every element is optimized for mobile and desktop, allowing players to register online, login, and start playing within minutes. Unlike many generic platforms in the online casino market, DK88 focuses on clarity, reliability, and speed. The interface is clean. The gameplay is smooth. The experience is built around player confidence. Built on Trust, Security, and Long-Term Commitment Trust is essential in online gaming. DK88 Casino prioritizes security at every level of the platform. Advanced encryption technology protects user data, ensuring a secure online casino website environment for Malaysian players. A dedicated support team is available 24/7 to assist with login issues, account questions, bonuses, and general support. The goal is simple: fast solutions and reliable assistance. This launch represents more than just a new online casino website. DK88 is building a long-term presence in Malaysia, with plans to expand its casino offering, introduce localized promotions, and develop strong connections within the Southeast Asia online gaming community. Welcome Bonus and Seamless Registration To celebrate its launch in Malaysia, DK88 Casino introduces a competitive welcome bonus for new members. Players who register online can claim additional gaming value and explore the full selection of online slots and live casino titles. The registration process is straightforward: Register online in minutes Login securely Claim the welcome bonus Start playing instantly DK88 Casino: Entertainment First DK88 positions itself as an entertainment-focused online casino platform. The experience is designed to combine technology, speed, and status-driven branding — a reflection of its Hero and Ruler-inspired identity. In a competitive Malaysia online casino market, DK88 stands out through: Secure and transparent gaming environment Wide online slot and live dealer selection Responsive 24/7 support team Fast registration and login process Attractive welcome bonus for new players Players in Malaysia and Singapore now have access to an online casino experience that combines energy, control, and reliability. Expanding Across Southeast Asia The Malaysia launch marks the first major step in DK88's regional expansion strategy. With Southeast Asia's online casino market growing steadily, the brand aims to strengthen its presence through continuous innovation, local promotions, and enhanced player engagement. Future developments include: Regular bonus campaigns Exclusive online slot releases Local partnerships Enhanced platform upgrades DK88 Casino is committed to becoming a leading online casino platform in Malaysia by maintaining transparency, performance, and long-term player trust. About DK88 Casino DK88 Casino is an international online casino platform focused on delivering secure, fast, and engaging gaming experiences. Designed for the modern Southeast Asia player, DK88 combines innovative technology with a reliable infrastructure. The brand's mission is clear: provide a trusted online casino environment where players can register online, claim bonuses, and enjoy a premium gaming experience with confidence. To explore the platform, visit the official website at dashking88official.com and discover the next generation of online casino entertainment in Malaysia. Media contact Brand: DK88 Contact: Media team Email: support@dashking88.com Website: https://dashking88official.com/

JIAXING, China – February 13, 2026 – On the eve of the 2026 Spring Festival, the “Relax Jiaxing” international promotional campaign, organized by the Jiaxing Municipal Bureau of Culture, Radio, Television, and Tourism in partnership with Putike International Travel Service,was successfully launched. The initiative invited celebrated Malaysian travel content creators @Janice&Jaguar on a curated three-day journey through Jiaxing, designed to capture the authentic flavors of the Chinese New Year and the timeless allure of the Jiangnan region. Documenting their experiences and sharing them with global audiences via Instagram, YouTube, and other international social media platforms, the influencers spotlighted Jiaxing’s vibrant Spring Festival traditions and distinctive Jiangnan character, extending an invitation to overseas travelers to “come back to Jiaxing and experience the festivities.” Where the Festive Spirit Reigns: Jiaxing Debuts Its Captivating “Chinese New Year Look” The meticulously curated itinerary, built around the theme of “New Year flavor,” linked a series of cultural landmarks immersed in festive ambiance. At Puyuan Fashion Ancient Town, the influencers marveled at the sweeping lantern displays, dazzling light installations, and strategically placed New Year decorations—while also bearing witness to the breathtaking spectacle of “Datiehua” (molten iron fireworks), an intangible cultural heritage performance that radiated both passion and romance, deeply rooted in traditional folk customs. On the iconic Yuehe Historical Street, home to distinctive attractions such as the Zongzi (rice dumpling) Museum, time-honored brands including Shendang rice wine and Weidefeng offered an authentic taste of local heritage. The bustling array of traditional New Year goods evoked cherished memories of a Jiaxing-style Spring Festival. Meanwhile, Nanhu Tiandi, Jiaxing’s most vibrant and trendy commercial district, has likewise embraced its festive transformation. Adorned with a series of celebratory art installations that seamlessly blend Jiangnan elegance with contemporary aesthetics, the area also hosts a lively New Year market running through the Lantern Festival. With photogenic scenes at every turn, the district embodies a stylish reinterpretation of traditional Chinese New Year spirit—where heritage meets modernity in the most captivating way. Encountering Ancient Jiangnan Towns: Immersing in the Slow Rhythms of Life Beyond the vibrant festive atmosphere, the influencers delved into Jiaxing’s rich tapestry of ancient cities and towns, exploring the city’s profound historical legacy across different eras and perspectives. At the Zicheng Archaeological Site Park, they wandered along the millennia-old city walls, listening to the silent stories embedded in every stone and experiencing the flow of Jiaxing’s history through centuries of change. Continuing to the Nanhu Tourist Resort, they ascended the iconic Misty Rain Pavilion against a backdrop of mist and drizzle, taking in sweeping views of Nanhu Lake and gazing upon the historic Red Boat—a timeless symbol enshrined in China’s revolutionary memory. At this convergence of red culture and Jiangnan scenery, they came to appreciate the city’s layered cultural identity. As night descended, an evening boat cruise offered a poetic conclusion to the day’s journey, weaving together the shimmering lights of Jiaxing’s waterfront. Gliding along the calm waters, the boat revealed a panorama of architectural silhouettes lining the shores—each telling its own story—unfolding like a living scroll of a “city that never sleeps,” both timeless and enchanting. “To Discover the Soul of Jiangnan’s Ancient Towns, Look to Jiaxing.” Xitang and Shendang unfold like two quietly turned pages from the chronicles of authentic Jiangnan life. Xitang Ancient Town, celebrated as a “living millennium-old town,” preserves remarkably intact clusters of Ming and Qing architecture, defined by its signature layout of “numerous bridges, winding lanes, and sheltered corridors.” Here, time seems suspended in a gentle, harmonious rhythm. Shendang Ancient Town, by contrast, offers a more tranquil and introspective experience. Largely untouched by excessive commercial development, it allowed the influencers to immerse themselves in the unspoiled, slow-paced essence of Jiangnan life. This journey by the Malaysian content creators stands as a vivid testament to Jiaxing’s cultural tourism vision—using the Spring Festival as a cultural bridge to share the refined aesthetics of Jiangnan with the world. Where time-honored New Year traditions converge with the legacy of ancient towns, and where revolutionary heritage intertwines with contemporary luminous artistry, Jiaxing reveals its uniquely inclusive and multifaceted character. It is crafting a fresh narrative for Spring Festival travel—one that blends festive richness with heartfelt experiences. Come, and discover a different kind of Jiangnan Chinese New Year.

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape. According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge. Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.” The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time. Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music. Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone. This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates. About Dr. Don Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression. Media Contact Dr. Don E: don@drdonmusic.com W: https://drdonmusic.com/

Historic insurance partnership with Great American Insurance Group sets new standard for player protection KUALA LUMPUR, Malaysia – February 09, 2026 – (SeaPRwire) – playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX’s continued commitment to strengthening financial safeguards for players across its platform. Official Video: https://www.youtube.com/watch?v=EpvceD-HJyU What This Means for Players The policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history. Direct claim rights with Great American Insurance Group Platform insolvency protection for all player funds Backed by GAI’s 30-year track record in gaming insurance Guinness-verified player protection in online gaming “This isn’t just a title — it’s a guarantee that our players’ funds are protected by an independent, globally recognized insurer, not just our promises,” said Mark Carter, CEO of playX. About playX Premier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security. About Great American Insurance Group Century-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995. Official Channels Facebook: https://www.facebook.com/playX.my Instagram: https://www.instagram.com/playx.my/ Telegram: https://t.me/playXofficial YouTube: https://www.youtube.com/@playXOfficial8 Media contact Brand: playX Contact: Media team Email: marking@playxgaming.com Website: https://playx.my